Skip to main content
. Author manuscript; available in PMC: 2014 Sep 1.
Published in final edited form as: Oral Oncol. 2013 Jul 23;49(9):893–902. doi: 10.1016/j.oraloncology.2013.06.011

Figure 3. In vivo efficacy of vascular disruption in combination with chemotherapy against subcutaneous FaDu tumor xenografts.

Figure 3

Change in tumor volumes of individual animals in control (A), VDA (B; DMXAA 25 mg/kg, i.p, once a week for 3 weeks), chemotherapy (C; Docetaxel 20 mg/kg, i.p. once a week for 3 weeks) and combination groups (n=8-14 mice per group) (D) over the 60-day monitoring period. Kaplan-Meier survival analysis of animals in all 4 groups is also shown (E). Combination treatment conferred a significant survival benefit compared to control (p<0.0001), VDA alone (p<0.05) and chemotherapy alone (p<0.01) (n=8-14 mice per group).